Breaking News

Celerion Enters Korean Drug Development Pact

May 29, 2014

Aims to enhance early phase clinical research in South Korea

Celerion and the Korean Drug Development Fund (KDDF) have entered a collaboration to provide drug development expertise and support for the emerging drug discovery and development industry in South Korea. 
 
The agreement provides the framework for collaborations of mutual benefit to both organizations. Companies funded by KDDF will have access to Celerion’s expertise in early clinical research and bioanalysis, as well as external partner sites. The collaboration will support a sharing of knowledge between KDDF and Celerion, and will focus on developing innovative and efficient ways to bring Korean drug discoveries to the global market.
 
“We are delighted to collaborate with KDDF, and provide early clinical research expertise to support and strengthen the emerging pharmaceutical industry in South Korea,” said Susan Thornton Ph.D., president and chief executive officer of Celerion. “Our agreement with KDDF is further evidence of Celerion’s enthusiasm and commitment to contributing to the growth of South Korea’s biomedical research industry.” 
 
“The KDDF is very happy to have established a partnership with Celerion. This collaboration is aligned to our vision to build effective partnerships between government, industry and academia,” said Dongho Lee MD, chief executive officer of KDDF. “Together with Celerion, KDDF will be able to provide professional consulting services to the Korean research communities to advance the research activities and promote important innovation.”

Related Contract Manufacturing:

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research